Quadrant Biosciences announced that the US Patent and Trademark Office (USPTO) has awarded the company and two of its academic partners, the State University of New York Research Foundation and the Penn State Research Foundation, with US Patent No.11,453,914 for the analysis and prediction of mild traumatic brain injury (mTBI) and concussion symptoms. This research was first mentioned on CNN in 2017. This patent is a “transformative piece of intellectual property” that Quadrant Biosciences is using to develop its Clarifi™ mTBI Saliva Test, expected to be available in late 2023. Quadrant has started discussions about potentially licensing this technology to third parties. This test uses small non-coding RNAs found in the saliva to help diagnose concussions.
“My son sustained a serious concussion in a youth hockey game. That’s when I discovered there needed to be a better, more exact way to diagnose concussions. I started Quadrant Biosciences in 2015 in Syracuse, NY on the foundation of improving the lives of children and families,” said Rich Uhlig, CEO and Founder of Quadrant Biosciences. “Seeing this patent come through is a realization of goals set seven years ago.”
The patented research was led by Dr Frank Middleton, PhD, Professor at SUNY Upstate Medical University, and Dr Steve Hicks, MD, PhD, now at Penn State College of Medicine, and focused on young adult and pediatric populations, who are most at risk for head injuries.
“Our motivation for developing this technology was to prevent further harm to the kids, athletes, and adults who experience mild, moderate, or repetitive head impacts,” said Middleton. “While most of the field has focused on peripheral blood measures, for the past decade we worked extensively to establish the utility of quantifying small RNA molecules in saliva as predictors of concussion or long-lasting symptoms from head impacts.”
Hicks said, “As a pediatrician who provides medical care for children and teens with concussion, I am excited by the potential of this technology to improve the way clinicians manage this common injury. A saliva-based test for concussion could provide a novel addition to the physician toolbox.”
This is the second patent awarded in less than one year to Quadrant and its partners. In March 2022, a patent was issued from the USPTO for its development of a saliva-based, epigenetic autism diagnostic aid; this same technology received FDA Breakthrough Device designation in April 2021, according to the company’s announcement. The company will continue to leverage its novel use of next-generation sequencing technology combined with advanced bioinformatics and machine learning techniques to develop and validate new diagnostics for other neurological conditions. Quadrant, as well as a National Institutes of Health (NIH) grant, are funding the development of these commercial tests.
Source: Quadrant Biosciences
Images: Quadrant Biosciences